May 17, 2024 8:30am EDT Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
May 15, 2024 4:05pm EDT Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Mar 21, 2024 4:05pm EDT Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
Jan 04, 2024 4:05pm EST Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
Dec 20, 2023 4:05pm EST Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Nov 16, 2023 8:00am EST Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
Nov 16, 2023 12:00am EST Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Nov 09, 2023 4:05pm EST Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
